Use of newly available febuxostat in a case of chronic tophaceous gout contraindicated to allopurinol and probenecid
Urate lowering therapy in this country has mainly been achieved by the use of allopurinol and probenecid. A new xanthine oxidase inhibitor called febuxostat has been approved in 2009 for treatment of hyperuricaemia in gout. In this report, we describe the management of a patient with chronic tophace...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English English |
| Published: |
Malaysian Medical Associations
2012
|
| Subjects: | |
| Online Access: | http://irep.iium.edu.my/29313/ http://irep.iium.edu.my/29313/ http://irep.iium.edu.my/29313/1/Use_of_Newly_Available_Febuxostat_in_a_Case_of_Chronic.pdf http://irep.iium.edu.my/29313/4/58485_Use%20of%20newly%20available%20f_scopus.pdf |